NBIX Earnings Date: Nov 2, 2026 (Estimated) — Neurocrine Biosciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is NBIX's next earnings date?
Neurocrine Biosciences, Inc. (NBIX) is expected to report Q3 2026 earnings on Monday, November 2, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.92 on revenue of $1.04B.
How did NBIX do in its last earnings report?
In its most recent report on Jul 30, 2026 (Q2 2026), Neurocrine Biosciences, Inc. posted EPS of $2.85 versus the $2.10 estimate, a beat of 35.7%. Revenue was $959.0M against a $876.6M estimate. The stock's 1-day post-earnings move was -10.1%.
How much does NBIX stock move after earnings?
NBIX beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.5% (up or down) in the day after earnings.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | Q2 2026 | 2.10 | 2.85 | +35.71% | $959.0M | ✅ Beat | -10.08% | -13.84% | -16.95% |
| 2026-05-05 | Q1 2026 | 1.61 | 1.94 | +20.50% | $814.5M | ✅ Beat | +8.86% | +15.36% | +23.91% |
| 2026-02-11 | Q4 2025 | 2.09 | 1.88 | -10.05% | $805.5M | ❌ Miss | -10.43% | -5.34% | -5.57% |
| 2025-10-28 | Q3 2025 | 1.87 | 2.17 | +16.04% | $794.9M | ✅ Beat | -6.35% | -2.84% | +2.85% |
| 2025-07-30 | Q2 2025 | 1.27 | 1.65 | +29.92% | $687.5M | ✅ Beat | -6.24% | -6.09% | +1.59% |
| 2025-05-05 | Q1 2025 | 1.09 | 0.70 | -35.78% | $572.6M | ❌ Miss | +8.36% | +9.73% | +13.46% |
| 2025-02-06 | Q4 2024 | 1.71 | 1.69 | -1.17% | $627.7M | ❌ Miss | -18.53% | -22.35% | -26.34% |
| 2024-10-30 | Q3 2024 | 1.51 | 1.81 | +19.87% | $622.1M | ✅ Beat | +7.01% | +4.60% | +8.95% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $959.0M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 99.5% | $954.3M | +39.9% | $621.2M | $563.7M | $682.0M | $789.9M |
| Collaboration Revenue | 0.5% | $4.7M | -14.5% | $6.5M | $8.9M | $5.5M | $5.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.